Aritz Lafuente

Mr. Aritz Lafuente

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ARArnau Biosca Romanillos
Arnau Biosca Romanillos
MRMiriam Ramirez
Miriam Ramirez
AGAlex Gomez-Gomez
Alex Gomez-Gomez
ALAritz Lafuente
Aritz Lafuente
VIValentín Iglesias
Valentín Iglesias
Xavier Fernàndez-BusquetsXavier Fernàndez-Busquets
Xavier Fernàndez-Busquets
The evolution of resistance by the malaria parasite to artemisinin, the key component of the combination therapy strategies that are at the core of current antimalarial treatments, calls for the urgent identification of new fast-acting antimalarials. The apicoplast organelle is a preferred target of antimalarial drugs because it contains biochemical processes absent from the human host. Fosmidomycin is the only drug in clinical trials targeting the apicoplast, where it inhibits the methyl erythritol phosphate (MEP) pathway. Here, we characterized the antiplasmodial activity of domiphen bromide (DB), another MEP pathway inhibitor with a rapid mode of action that arrests the in vitro growth of Plasmodium falciparum at the early trophozoite stage. Metabolomic analysis of the MEP pathway and Krebs cycle intermediates in 20 µM DB-treated parasites suggested a rapid activation of glycolysis with a concomitant decrease in mitochondrial activity, consistent with a rapid killing of the pathogen. These results present DB as a model compound for the development of new, potentially interesting drugs for future antimalarial combination therapies.